Target
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H]
Ligand
BDBM287859
Substrate
n/a
Meas. Tech.
R132H IDH1 Enzymatic Assay
IC50
17.0±n/a nM
Citation
 Fischer, CBogen, SLChilders, MLFradera Llinas, FXEllis, JMEsposite, SHoffman, DMHuang, CKattar, SDKim, AJLampe, JWMachacek, MRMcMasters, DRParker, Jr., DLReutershan, MHSciammetta, NShao, PPSloman, DLSun, WUjjainwalla, FWu, ZYu, YGibeau, CR Tricyclic compounds as inhibitors of mutant IDH enzymes US Patent  US10508108 Publication Date 12/17/2019 
Target
Name:
Isocitrate dehydrogenase [NADP] cytoplasmic [R132H]
Synonyms:
Cytosolic NADP-isocitrate dehydrogenase (IDH1)(R132H) | IDH1 | IDH1 R132H | IDH1(R132H) | IDHC_HUMAN | Isocitrate dehydrogenase (IDH1)(R132H) | Isocitrate dehydrogenase 1 mutant (R132H) | Isocitrate dehydrogenase [NADP] cytoplasmic (IDH)(R132H) | Isocitrate dehydrogenase [NADP] cytoplasmic (IDH1)(R132H) | Isocitrate dehydrogenase [NADP] cytoplasmic (R132H) | PICD
Type:
Protein
Mol. Mass.:
46641.74
Organism:
Homo sapiens (Human)
Description:
Human IDH1 R132H (SEQ ID No. 2 in patent). First three are removed. Google patent parsed wrong.
Residue:
414
Sequence:
MSKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDEKRVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGHHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL
  
Inhibitor
Name:
BDBM287859
Synonyms:
6-[(2R)-2,3-dihydro-1,4- benzodioxin-2-ylcarbonyl]- 8-[(1R,5S)-8-oxa-3- azabicyclo[3.2.1]oct-3-yl]- 6,11-dihydro-5H- pyrido[2,3-b] [1,5]benzodiazepine | US10086000, Example 76 | US10508108, Example 76
Type:
Small organic molecule
Emp. Form.:
C27H26N4O4
Mol. Mass.:
470.5197
SMILES:
O=C([C@H]1COc2ccccc2O1)N1Cc2cccnc2Nc2ccc(cc12)N1C[C@@H]2CC[C@H](C1)O2 |r|
Structure:
Search PDB for entries with ligand similarity: